



June 6, 2016

CareDx to Host Call to Provide First Analysis of Data from DART Study

Conference Call to be Held on June 13, 2016 at 4pm ET

BRISBANE, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will host a conference call on June 13, 2016 at 4:00 pm ET to provide initial results from the company's DART study.

During the call, Dr. Daniel C. Brennan, MD, FACP, Director of Transplant Nephrology at Washington University School of Medicine in St. Louis, Missouri, will provide clinical perspectives on the first analysis of data from the DART study. Peter Maag, PhD, Chief Executive Officer of CareDx, John Sninsky, PhD, Chief Scientific Officer and James Yee, MD, PhD, Chief Medical Officer will also participate on the call.

Daniel C. Brennan, MD, FACP, is the Alan A. and Edith L. Wolff Professor of Renal Diseases and the Director of Transplant Nephrology at Washington University School of Medicine in St. Louis, Missouri. Dr. Brennan's research interests are viral infections, induction immunosuppression therapy, and pharmaco-economic and outcome research in transplantation and islet transplantation. He has written more than 200 original publications and several textbooks in these areas.

Conference Call Information

Individuals interested in listening to the conference call may do so by dialing 1-855-420-0616 for domestic callers or 1-678-304-6848 for international callers. Please reference Conference ID 27585467. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.caredx.com.

A replay of the call will be available beginning June 13, 2016 at 4:00pm PT/ 7:00pm ET until 4:00 pm PT/ 7:00pm ET on June 14, 2016. To access the replay, dial 1-855-859-2056 or 1-855-859-2056 and reference Conference ID: 27585467. The webcast will also be available on CareDx's website for one year following the completion of the call.

About the DART Study

The Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study is a prospective, multicenter, observational study of de-novo kidney transplant subjects where blood specimens will be drawn periodically after transplant and also after treatment for acute rejection.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. The company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation.

CareDx's, with its presence through Olerup AB, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP®, a set of HLA typing is used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation; and XM-ONE®, the first standardized test that quickly identifies a patient's antigens against HLA Class I, Class II or antibodies against a donor's endothelium. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that may not be successful in our efforts to

develop and commercialize diagnostic tests based on sequencing cell-free DNA. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in CareDx's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, and Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to CareDx, and CareDx assumes no obligation to update any such forward-looking statements.

Media Contacts - CareDx

Molly Martell, Senior Director, Marketing

T: +1 415-728-6307

E: [mmartell@caredx.com](mailto:mmartell@ caredx.com)

Media Contacts - Investor

Jamar Ismail, Vice President

Westwicke Partners, LLC

T: +1 415-513-1282

E: jamar.ismail@westwicke.com

 [Primary Logo](#)

Source: CareDx, Inc.

News Provided by Acquire Media